Expression of poly (Adenosine Diphosphate-Ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome

International Journal of Gynecological Pathology

Volumn 30, Issue 2, 2011, Pages 139-144

  Godoy, Heidi ^a   Mhawech Fauceglia, Paulette ^a   Beck, Amy ^a   Miller, Austin ^a   Lele, Shashikant ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Epithelial ovarian cancer; Immunoexpression; Outcome; p53; PARP

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79951772907     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181fa5a64     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-79. (Pubitemid 44636248)
3. Lee CK, Pires de Miranda M, Ledermann JA, et al. Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy. Eur J Cancer 1999;35:727-32. (Pubitemid 29258141)
4. Polverino G, Parazzini F, Stellato G, et al. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol 2005;99:343-7. (Pubitemid 41502841)
5. Chu CS, Kim SH, June CH, et al. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008;8:243-57. (Pubitemid 351385915)
6. Dantzer F, de La Rubia G, Menissier-De Murcia J, et al. Base excision repair is impaired in mammalian cells lacking poly (ADP-ribose) polymerase-1. Biochemistry 2000;39:7559-69. (Pubitemid 30422075)
7. Schreiber V, Dantzer F, Ame JC, et al. Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28. (Pubitemid 44036457)
8. De Murcia G, Menissier de Murcia J. Poly (ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994;19:172-6. (Pubitemid 24115433)
9. Ruf A, de Murcia G, Schulz GE. Inhibitor and NAD binding to poly (ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 199817;37:3893-900.
10. Bowman KJ, Newell DR, Calvert AH, et al. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001;84:106-12. (Pubitemid 32102513)
11. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly (ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
12. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54: 375-429.
13. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
14. Creasman WT. Announcements: FIGO stages: 1988 revision. Gynecol Oncol 1989;35:125-7.
15. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82:893-901. (Pubitemid 28104169)
16. Moch H, Kononen T, Kallioniemi OP, et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001;8:14-20.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7. (Pubitemid 28331029)
18. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003;97:389-404. (Pubitemid 36133806)
19. Ratnam K, Low JA. Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8. (Pubitemid 46450426)
20. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(suppl 5):10-17. (Pubitemid 39658341)
21. Brustmann H. Poly (adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 2007;26: 147-53. (Pubitemid 46573210)
22. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504. (Pubitemid 38436523)
23. Gien LT, Mackay HJ. The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer. J Oncol 2010;2010:151750.
24. Helleday T, Bryant HE, Schultz N. Poly (ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005;4:1176-8. (Pubitemid 41365386)
25. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADPribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
26. Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Curr Clin Pharmacol 2010;5: 192-5.
27. Amir E, Seruga B, Serrano R, et al. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev 2010;36:557-65.
28. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-9.